Basic Levitra With Dapoxetine Information

• INN (International Nonproprietary Name): Vardenafil with Dapoxetine. Vardenafil treats erectile dysfunction (ED) and dapoxetine treats premature ejaculation (PE). The combination is marketed under combined brand names in multiple countries.
• Brand Names Available In Canada (English): not specified.
• ATC Code: Vardenafil G04BE09; Dapoxetine G04BX14.
• Forms & Dosages: Film-coated tablets. Common strengths are 20 mg Vardenafil / 60 mg Dapoxetine and 40 mg Vardenafil / 60 mg Dapoxetine. Typical pack sizes are 4, 10 or 20 tablets.
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): not specified.
• OTC / Rx Classification: Prescription-only (Rx) in most markets according to available product information.

Key Findings From Recent Trials (Research-First)

Patients ask whether the fixed-dose combination actually works better than treating each condition separately.

High-quality Canada-specific randomized controlled trials of vardenafil with dapoxetine are absent through 2025.

Most controlled evidence comes from small randomized trials and open-label studies in India and other Asian countries.

Typical studied doses were 20 mg vardenafil combined with 60 mg dapoxetine, and sometimes 40 mg/60 mg formulations.

Meta-analyses and safety reviews up to 2025 report improvements in International Index of Erectile Function (IIEF) scores versus baseline when both mechanisms are combined.

These reviews also consistently note increased intravaginal ejaculatory latency time (IELT) compared with baseline when dapoxetine is part of therapy.

Effect sizes across studies are heterogeneous, reflecting small samples and variable designs.

No centrally authorised fixed-dose product exists in the EU or US, and regulatory reviews have flagged insufficient Western-market pharmacovigilance data.

Post-marketing reports and pharmacy complaint logs identify expected adverse-event clusters associated with PDE5 inhibitors and short-acting SSRIs.

Commonly reported events include headache, flushing, dizziness, insomnia and, rarely, serotonin-related events.

Increased adverse-event reporting is seen when patients take strong CYP3A4 inhibitors or nitrates concurrently.

Main Outcomes

Combination treatment shows dual symptomatic benefit when ED and PE coexist in the same patient.

IIEF improvements are reported for erectile function domains compared with baseline in multiple small trials.

IELT prolongation is reproducible across dapoxetine-containing studies and is usually dose-dependent.

Heterogeneity limits extrapolation to broad Canadian populations and to long-term outcomes.

Safety Observations

Safety reports generally reflect the known profiles of vardenafil and dapoxetine given together.

Headache, flushing and dizziness are the most frequent treatment-emergent complaints.

Insomnia, nausea and transient vision symptoms are described and align with vardenafil or dapoxetine effects.

Rare serotonin-related events and orthostatic hypotension have been reported, particularly with interacting medicines.

Regulators note a lack of long-term Western-market pharmacovigilance data for the fixed-dose product.

Clinical Mechanism Of Action

People often wonder how one tablet can tackle both erection and ejaculation concerns.

The fixed-dose tablet pairs a phosphodiesterase type 5 (PDE5) inhibitor with a short-acting selective serotonin reuptake inhibitor (SSRI).

Vardenafil increases penile blood flow to help achieve and maintain erections.

Dapoxetine delays ejaculation by enhancing serotonergic inhibition in ejaculatory pathways.

Layman’s Explanation

Think of vardenafil as the blood‑flow booster and dapoxetine as the timing controller.

Vardenafil helps the penis fill and stay firm by easing smooth muscle relaxation in the corpus cavernosum.

Dapoxetine makes the reflex that triggers ejaculation less sensitive, so intercourse can last longer before climax.

Used together, they address both problems for men who experience ED and PE at the same time.

Scientific Breakdown

Vardenafil selectively inhibits PDE5, raising cyclic guanosine monophosphate (cGMP) in corpus cavernosum smooth muscle.

Elevated cGMP enhances nitric-oxide–mediated vasodilation and facilitates erection during sexual stimulation.

Dapoxetine inhibits presynaptic serotonin reuptake, increasing synaptic serotonin concentrations in central pathways involved in ejaculatory control.

Improved serotonergic tone correlates with prolonged intravaginal ejaculatory latency time (IELT).

The two mechanisms are pharmacologically complementary but add overlapping safety considerations, notably blood-pressure changes and serotonin effects.

Pharmacokinetics & Interactions

Common marketed fixed doses are 20/60 mg and 40/60 mg (vardenafil/dapoxetine).

Vardenafil is primarily metabolized by CYP3A4.

Dapoxetine is metabolized mainly by CYP2D6 and also by CYP3A4.

Co-administration with strong CYP3A4 inhibitors can raise plasma levels of vardenafil and possibly dapoxetine, increasing adverse events.

Concurrent use of nitrates is an absolute contraindication because of the risk of profound hypotension.

Scope Of Approved & Off-Label Use

Canadians frequently ask whether the combined tablet is approved here and covered by public plans.

As of July 2025 the fixed-dose vardenafil plus dapoxetine combination has no known Health Canada Marketing Authorisation or DIN.

Both agents exist as individual therapies in some jurisdictions, but the fixed combination is marketed in India, some CIS countries and by online sellers.

Health Canada Approvals (DIN-Based)

No Drug Identification Number (DIN) for the fixed-dose vardenafil+dapoxetine product is recorded in available product information.

Without a DIN the fixed product cannot be routinely marketed or listed on provincial formularies in Canada.

Standalone products—vardenafil or dapoxetine as single agents—may have separate regulatory statuses in different countries.

Notable Off-Label Trends In Canadian Practice

Some Canadian prescribers and patients prefer to use licensed single agents in tailored regimens rather than an imported fixed tablet.

Community pharmacists report occasional cross-border imports by patients seeking the convenience of a single pill for ED and PE.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ generally do not list imported fixed-combination products.

Reimbursement for an unapproved imported tablet is unlikely without a DIN or special exception.

Dosage Strategy

Patients routinely ask how to take a combined tablet and what to start with.

Marketed fixed-dose tablets commonly appear as 20 mg vardenafil with 60 mg dapoxetine or 40 mg/60 mg variants.

General Dosing Per Health Canada Monographs

Product labeling from available information recommends a single tablet 30–60 minutes before sexual activity and no more than one tablet per 24 hours.

Because the fixed product lacks a Health Canada DIN, Canadian prescribers normally guide dosing from monographs for the individual agents.

On-demand use is the intended regimen rather than daily continuous dosing.

Condition-Specific Dosing Adjustments

For patients with both ED and PE, start with the lower vardenafil strength (20 mg) when cardiovascular comorbidity exists.

Use 60 mg dapoxetine for ejaculation control unless contraindicated by psychiatric history or interacting medications.

Elderly patients should begin cautiously at lower exposure levels and be monitored for hypotension or dizziness.

Moderate to severe hepatic or renal impairment is a contraindication in available product information.

Patients taking strong CYP3A4 inhibitors should reduce dose or avoid the combination.

Safety Protocols

Before a first dose patients want a list of absolute no-goes and what to watch for.

Contraindications (Canadian Advisories)

Use is contraindicated with nitrates because of severe hypotension risk.

Recent myocardial infarction, stroke or unstable cardiac disease are contraindications.

Moderate to severe hepatic or renal impairment is also a contraindication.

Concurrent MAOIs, thioridazine or other SSRIs are contraindicated with dapoxetine.

Age below 18 years and known hypersensitivity to either active ingredient are absolute exclusions.

Adverse Effects (Post-Market Reports)

Common mild-to-moderate events include headache, flushing and dizziness.

Nasal congestion, nausea, insomnia and mild vision changes are also reported.

Dapoxetine commonly causes anxiety or restlessness in some patients.

Post-marketing safety signals include orthostatic hypotension, rare serotonin syndrome where additional serotonergic drugs are present, and priapism in predisposed patients.

Canadian pharmacy counselling focuses on cardiovascular assessment, nitrates screening, and educating patients to seek urgent care for erection lasting longer than four hours or for signs of serotonin syndrome.

Interaction Mapping

Practical counselling covers common food and drug interactions the patient will encounter in Canada.

Food Interactions Common In Canadian Diet

High‑fat meals delay vardenafil absorption and can delay onset of effect.

Large evening meals common in social dining settings may push the onset beyond the 30–60 minute window.

Alcohol increases vasodilation and can make dizziness or orthostatic symptoms more likely.

Drug Combinations Flagged By Health Canada

Concurrent use of nitrates is an absolute contraindication and must be avoided.

Alpha‑blockers can cause additive hypotension, so dose spacing and monitoring are important.

Strong CYP3A4 inhibitors such as ketoconazole, itraconazole and some macrolide antibiotics raise vardenafil levels and increase adverse events.

Concomitant SSRIs, MAOIs, or other serotonergic drugs increase the risk of serotonin syndrome with dapoxetine.

Over‑the‑counter remedies and herbals like St. John’s wort can alter CYP metabolism or serotonergic tone and should be reviewed.

Patient Experience Analysis

Men ask how other Canadians find the combo in real life and what pharmacists see at the counter.

Canadian Survey Data

No large Canadian randomized trials exist for the fixed combination through 2025.

Available Canadian data mostly come from pharmacy consultation records and small patient surveys.

Men who obtain combination therapy report convenience and improved symptom control when ED and PE coexist.

Pharmacists note missed cardiovascular screening when patients source tablets online without professional review.

Forum & Community Pharmacy Trends

Canadian forums and cross‑border purchasing threads show variable efficacy reports and frequent price comparisons.

Adverse-effect disclosure on forums is less frequent than formal pharmacovigilance reporting, but serious events prompt medical visits.

Community pharmacists working in national chains recommend consulting prescribers, avoiding unverified online vendors and considering licensed alternatives dispensed under pharmacist supervision.

Distribution & Pricing Landscape

Patients often ask whether big chains stock the fixed‑dose tablet and how online prices compare.

National Pharmacy Chains

Major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs generally do not stock unapproved fixed-dose vardenafil+dapoxetine without a DIN.

Pharmacists at those chains do counsel patients who present imported products and can suggest licensed alternatives.

Online Pharmacy Availability & Provincial Restrictions

The fixed combination is widely offered by international e-pharmacies, particularly suppliers in India and China.

Canadian customers may import via mail order subject to customs rules and personal importation allowances.

Provincial formularies do not typically list the imported fixed combo and public reimbursement is unlikely.

Cross-Border US Comparisons

Retail e-pharmacies selling generics from India or China usually price combination tablets lower than purchasing separate licensed agents in Canada or the US.

However, cost savings must be weighed against the absence of a DIN, unclear GMP assurance and lack of provincial reimbursement.

Alternative Options

Many patients prefer licensed alternatives that allow tailored dosing and pharmacist oversight.

Comparison Of DIN-Approved Alternatives

Licensed PDE5 inhibitors in Canada include sildenafil and tadalafil, and vardenafil may be available as a single agent depending on market listings.

Dapoxetine as a single licensed product is not widely available in Canada, and clinicians sometimes use other SSRIs off-label for PE or recommend topical anesthetics and behavioural therapy.

Choosing separate licensed agents allows dose adjustments and clearer safety monitoring compared with an imported fixed tablet.

Pros And Cons Checklist

• Separate Licensed PDE5 + Supervised SSRI/Topical: Pros — adjustable dosing, DIN-backed quality, pharmacist monitoring; Cons — multiple medications and potential adherence issues.
• Fixed-Dose Imported Combo: Pros — single‑pill convenience and combined mechanism; Cons — no DIN, uncertain GMP, regulatory and reimbursement issues, and potential for unnoticed interactions.
• Non-Pharmacologic Options: Pros — no drug interactions; Cons — variable access and more time to effect.

Regulatory Status

Regulatory questions are common when patients consider ordering online or asking a prescriber for an imported product.

Health Canada Approval Process

Manufacturers must submit evidence of quality, safety and efficacy to obtain a Drug Identification Number (DIN) from Health Canada.

As of July 2025 the fixed-dose vardenafil+dapoxetine combination has no known DIN and is not centrally authorised in the EU or US.

Products sold as prescription generics in India are exported but are not Health Canada-approved.

DIN And Bilingual Labelling Rules

Canadian regulations require bilingual English/French labelling and GMP-compliant manufacturing for marketed drugs.

Routine commercial distribution without a DIN is not permitted.

Personal importation is possible in narrow circumstances but does not equate to market approval or formulary coverage.

Health Canada expects adverse-event reports for unlicensed imported medicines and clinicians should report suspected reactions to Canada Vigilance.

Consolidated FAQ

Q1: Is Levitra with dapoxetine approved in Canada?

A1: No fixed-dose vardenafil+dapoxetine product has a known Health Canada DIN as of 2025; single agents may be available.

Q2: Can I import it for personal use?

A2: Personal importation may be possible but carries risks: no DIN, variable quality and no provincial coverage; consult your pharmacist and prescriber first.

Q3: What are the main safety checks?

A3: Cardiovascular risk assessment (nitrate use), review of serotonergic medications, hepatic/renal function, and interactions with CYP3A4 inhibitors.

Q4: Will provincial drug plans cover it?

A4: Unlikely without a DIN or formulary listing; check Ontario Drug Benefit, BC PharmaCare or RAMQ for covered alternatives.

Q5: Who to contact for adverse effects?

A5: Seek urgent care for severe reactions; report to Health Canada (Canada Vigilance) and your pharmacist.

Visual Guide

Patients find infographics helpful for quick reference on dosing, coverage and purchase channels.

Suggested infographic assets include a dosage flowchart, a provincial coverage map, a purchase‑channel comparison and quick safety icons.

Dosage flowchart should show 20 mg/60 mg versus 40 mg/60 mg, timing 30–60 minutes and maximum 1 tablet per 24 hours.

Provincial coverage map should mark green where DIN-backed alternatives are commonly covered and red where the fixed combo is unlikely to be covered.

Purchase-channel graphic should contrast in-store licensed dispensing versus online import with risk callouts.

Safety icons should highlight nitrates (stop), CYP3A4 inhibitors (caution) and serotonin syndrome (seek help).

Design notes: include bilingual labels, Health Canada reporting guidance, and callouts to national chains for pharmacist consultation.

Storage & Transport

Patients frequently ask how to store imported tablets safely at home or when travelling.

Canadian Household Guidelines

Store tablets below 30°C and protect them from moisture and light.

Keep tablets in their original blister pack so expiry and labelling remain visible.

Avoid storing medication in bathroom cabinets that experience humidity; prefer a cool, dry place away from children.

Use pharmacy medication take-back programs to dispose of expired tablets responsibly.

Cold-Chain Storage Where Applicable

The fixed-dose tablets do not require cold‑chain storage but should not be exposed to prolonged temperatures above 30°C.

When importing, ensure packaging avoids extreme heat in summer and freezing in winter during transit.

Keep original prescription documentation and packaging when carrying medication across borders to aid customs and pharmacist review.

Guidelines For Proper Use

Pharmacists provide practical checks and follow-up steps that reduce risk and improve outcomes.

Advice From Canadian Pharmacists

Verify prescription validity and perform cardiovascular risk screening before advising on use.

Review all concomitant medications, including nitrates, SSRIs and CYP3A4 modulators.

Counsel patients to take the tablet on a lighter stomach to optimise the 30–60 minute onset window.

Warn patients not to take more than one tablet in 24 hours and to avoid combining with recreational nitrates.

Encourage patients to prefer DIN‑approved alternatives dispensed through Shoppers Drug Mart, Rexall, Jean Coutu or London Drugs when available.

Provincial Health Authority Guidance

Provincial authorities recommend prescription‑only access and cardiovascular assessment prior to starting PDE5 inhibitors.

Because the fixed-dose product lacks a DIN, provincial formularies will not typically list it.

Document rationale carefully if recommending an imported combination tablet and inform patients about the lack of local regulatory oversight.

Report suspected adverse reactions to Canada Vigilance when patients present after using imported products.

Purchase Context

In our online pharmacy, levitra with dapoxetine is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Delivery Across Canada (English)

Storage And Handling For Patients

Keep the blister pack label and expiry date visible for pharmacist reference.

Protect tablets from moisture and direct sunlight during storage and travel.

Use pharmacy disposal programs for expired or unused medication to avoid environmental release.

Final Safety Checklist For Clinicians

Confirm the indication is coexisting ED plus PE before recommending combination therapy.

Rule out absolute contraindications such as nitrate use, recent myocardial infarction or severe hepatic impairment.

Review all medications for CYP3A4 inhibitors and serotonergic agents that increase risk.

Advise on on-demand timing, limit to one tablet per 24 hours and schedule follow-up to assess efficacy and adverse events.

Report any suspected adverse reactions to Canada Vigilance when a patient presents after using an imported product.

Concluding Notes

The fixed-dose combination of vardenafil with dapoxetine provides an on-demand option targeting erectile dysfunction and premature ejaculation together.

Clinical evidence is encouraging but mainly comes from international studies with variable quality and limited Western pharmacovigilance data.

Canadian clinicians and pharmacists should prioritise cardiovascular screening, interaction checks and prefer DIN-approved alternatives when possible.

Patients considering imported combination tablets should consult a pharmacist or prescriber to review safety, procurement quality and legal considerations.